Samsung Pharm (001360) — Cash Flow Reinvestment Rate

Latest as of June 2022: 0.48x

Samsung Pharm (001360) has a Cash Flow Reinvestment Rate of 0.48x as of June 2022, reinvesting ₩766.26 Million (capex ₩638.30 Million plus investments ₩-127.95 Million) from operating cash flow of ₩1.59 Billion. Check Samsung Pharm earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.48x
(Capex + Investments) / Operating CF

Total Reinvested

₩766.26 Million
Capex + Investments

Operating Cash Flow

₩1.59 Billion
KRW

Capital Expenditures

₩638.30 Million
KRW

Samsung Pharm Cash Flow Reinvestment Rate (2017–2017)

Historical reinvestment intensity for Samsung Pharm across 1 annual periods. Explore Samsung Pharm long-term investment intensity to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Samsung Pharm (2017–2017)

Year-by-year capital reinvestment analysis for Samsung Pharm. For live market cap and broader valuation context, see 001360 stock market capitalisation.

Year Reinvestment Rate Total Reinvested (KRW) Operating CF Capex YoY Change
2017 1.26x ₩6.51 Billion ₩5.15 Billion ₩6.11 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow